Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Tazemetostat in Combination With Venetoclax in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT05618366 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT05618366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05618366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Tazemetostat in Combination With Venetoclax in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 1
Overall status
Terminated
Start date
June 7, 2023
Completion date
February 27, 2026
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma, lymphoma, non-hodgkin